SCHEMBL20399062

SCHEMBL20399062

O=C1CCCN1CCCNc1nc(NCc2ccccc2C(F)(F)F)c2sccc2n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 2/20 0.42
MKNK2 Q9HBH9 2/20 0.42
TYRO3 Q06418 7/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MAPK1 P28482 1/20 0.39
MET P08581 1/20 0.39
SELP P16109 1/20 0.39
AXL P30530 1/20 0.39
MERTK Q12866 1/20 0.39
MALT1 Q9UDY8 1/20 0.38
ULK1 O75385 1/20 0.38
ULK2 Q8IYT8 1/20 0.38
ADORA1 P30542 1/20 0.37
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
PGK1 P00558 1/20 0.37
KDM4E B2RXH2 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26741836 0.89 MKNK1 (0.41) MKNK1MKNK2TYRO3HTTSMN1; SMN2
SCHEMBL21542004 0.83 PDE4A (0.47) PDE4APDE4BPDE4CPDE4DKDM4E
SCHEMBL21541995 0.83 TYRO3 (0.54) MKNK1MKNK2TYRO3SMN1; SMN2MAPK1
SCHEMBL21542072 0.81 POLB (0.45) TYRO3METPDE4APDE4BPDE4C
SCHEMBL21542068 0.79 CYP1A2 (0.48) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL21542011 0.76 PAK4 (0.46) TYRO3METADORA1PDE4APDE4B
SCHEMBL21542013 0.76 RAD52 (0.42) TYRO3ADORA1PDE4APDE4BPDE4C
SCHEMBL26746206 0.76 PDE4A (0.46) TYRO3PDE4APDE4BPDE4CPDE4D
SCHEMBL20399303 0.75 PDE4A (0.45) TYRO3PDE4APDE4BPDE4CPDE4D
SCHEMBL21542038 0.74 EPHX2 (0.46) TYRO3METMERTKPDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190345157-A1 COMPOUNDS EISAI R&D MANAGEMENT CO., LTD. (JP) 2019-11-14 US claimed
WO-2018134685-A2 COMPOUNDS LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) 2018-07-26 WO claimed
US-12545675-B2 Anti-wolbachia pyrido[2,3-d]pyrimidine compounds LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) 2026-02-10 US disclosed
US-20230348460-A1 ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINECOMPOUNDS THE UNIVERSITY OF LIVERPOOL (GB) 2023-11-02 US disclosed
US-20230348460-A1 ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINECOMPOUNDS THE UNIVERSITY OF LIVERPOOL (GB) 2023-11-02 US disclosed
US-20230348460-A1 ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINECOMPOUNDS THE UNIVERSITY OF LIVERPOOL (GB) 2023-11-02 US disclosed
US-11518760-B2 Anti-Wolbachia pyrido[2,3-d]pyrimidine compounds LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) 2022-12-06 US disclosed
US-20190345157-A1 COMPOUNDS EISAI R&D MANAGEMENT CO., LTD. (JP) 2019-11-14 US disclosed
US-20190345157-A1 COMPOUNDS EISAI R&D MANAGEMENT CO., LTD. (JP) 2019-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545675-B2 Anti-wolbachia pyrido[2,3-d]pyrimidine compounds CBR1, CBR3, COX6C MKNK1 4150/4885MKNK2 3896/4885TYRO3 999/4885
US-20230348460-A1 ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINECOMPOUNDS PWWP2B, WARS1, PNPO MKNK1 2051/4885MKNK2 2028/4885TYRO3 1972/4885
US-20190345157-A1 COMPOUNDS ABCB11, LTC4S, AQP1 MKNK1 3908/4885MKNK2 3968/4885TYRO3 2805/4885
US-11518760-B2 Anti-Wolbachia pyrido[2,3-d]pyrimidine compounds P2RX5, PNPO, P2RX3 MKNK1 2342/4885MKNK2 2374/4885TYRO3 1572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.